Table 1.

Characteristics of 8 randomized controlled trials of intermittent vs continuous androgen deprivation therapy in metastatic or recurrent prostate cancer patients

Authors	Patients’ Diagnosis	Total Sample Size	Median Age	ADT Regimen	IADT Definition	Median Follow-up (y)
de Leval et al (2002)	Mixed	68	72	GnRH + antiandrogen	PSA level	2.4
Irani et al (2008)	Mixed	129	73	GnRH + antiandrogen	6-month block	3.6
Calais da Silva et al (2009)	Mixed	626	73	GnRH + antiandrogen	PSA level	4.3
Langenhuijsen et al (2011)	Metastatic	193	68	GnRH + antiandrogen	PSA level	2.6
Salonen et al (2012)	Mixed	554	72	GnRH only	PSA level	5.4
Mottet et al (2012)	Metastatic	173	69	GnRH + antiandrogen	PSA level	3.7
Hussain et al (2012)*	Metastatic	1535	–	GnRH + antiandrogen	PSA level	9.2
Crook et al (2012)	Recurrent	1386	74	GnRH only	PSA level	6.9

ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone; IADT, intermittent androgen deprivation therapy; PSA, prostate-specific antigen.

^*Published in an abstract form.